Table 5.
Patients | Proportion (%) of peptide-reactive T cell blasts expressing cytokines | |||
---|---|---|---|---|
CD4+ IFN-γ+ | CD4+IL-4+ | CD8+ IFN-γ+ | CD8+IL-4+ | |
02.CC | 11.2 | 0.11 | 15.1 | 0.19 |
03.CA | 12.1 | <0.1 | 12.8 | <0.1 |
04.FM | 6.2 | <0.1 | 10.3 | <0.1 |
05.PF | 10.0 | 0.10 | 11.9 | 0.18 |
06.CAn | 11.9 | <0.1 | 16.3 | 0.20 |
08.DN | 10.9 | 0.20 | 13.9 | 0.10 |
09.BG | 7.8 | <0.1 | 10.0 | <0.1 |
10.BA | 10.3 | <0.1 | 13.0 | <0.1 |
11.BS | 8.1 | <0.1 | 9.1 | <0.1 |
12.BG | 8.9 | <0.1 | 10.8 | <0.1 |
13.MS | 11.9 | 0.10 | 12.7 | 0.17 |
14.AC | 7.0 | <0.1 | 10.1 | <0.1 |
17.MM | 7.2 | <0.1 | 10.3 | 0.39 |
18.SB | 11.8 | 0.19 | 15.0 | <0.1 |
19.AB | 15.1 | 0.18 | 16.2 | <0.1 |
20.BF | 10.1 | <0.1 | 11.4 | <0.1 |
Intracytoplasmic IL-4 and IFN-γ positive T cell blasts of PBMC-derived peptide-specific T cell lines. GCAA peptide specific T cell lines were obtained from 16 of 20 patients with gastric adenocarcinoma. T cell blasts were stimulated with peptides (10 μg/ml) and intracellular cytokine synthesis was evaluated by cytofluorometric analysis. Results represent mean proportions of cytokine-positive cells over the background values obtained with isotype-control monoclonal antibodies